Review
Medicine, General & Internal
Ciro Mauro, Valentina Capone, Rosangela Cocchia, Filippo Cademartiri, Ferdinando Riccardi, Michele Arcopinto, Maie Alshahid, Kashif Anwar, Mariano Carafa, Andreina Carbone, Rossana Castaldo, Salvatore Chianese, Giulia Crisci, Roberta D'Assante, Mariarosaria De Luca, Monica Franzese, Domenico Galzerano, Vincenzo Maffei, Alberto M. Marra, Valeria Valente, Federica Giardino, Alfredo Mazza, Brigida Ranieri, Anna D'Agostino, Salvatore Rega, Luigia Romano, Sarah Scagliarini, Chiara Sepe, Olga Vriz, Raffaele Izzo, Antonio Cittadini, Eduardo Bossone, Andrea Salzano
Summary: Cardiovascular diseases are a major cause of morbidity and mortality among cancer survivors, particularly breast cancer survivors. The use of certain chemotherapeutics in breast cancer treatment can lead to cardiac dysfunction. Therefore, it is important to have a multidisciplinary approach for preventing, detecting, and treating cardiotoxicity in breast cancer patients.
JOURNAL OF CLINICAL MEDICINE
(2023)
Review
Oncology
Jakub Bychowski, Wojciech Sobiczewski
Summary: Cancer and cardiac diseases are the leading causes of death in developed countries. Due to advancements in detection and treatment, more cancer patients are surviving and living longer. However, there is an increasing risk of cardiovascular complications from cancer therapies, such as heart dysfunction and premature heart disease. Cardio-oncology is a new field that focuses on screening, diagnosis, and prevention of these adverse effects. This review discusses the most relevant studies on cardiac effects of oncological therapy and methods for prevention.
Article
Oncology
Sally Cohen-Cutler, Cameron Kaplan, Arthur Olch, Kenneth Wong, Jemily Malvar, Louis S. Constine, David R. Freyer
Summary: The background screening guidelines for childhood cancer survivors treated with radiation currently rely on broad anatomic irradiated regions (IR) to determine the risk for late effects. This article compares the projected healthcare costs associated with using volumetric dosimetry (VD) versus broad anatomic irradiated regions screening to determine radiation-related late effects screening recommendations for survivors of childhood cancer.
Article
Pediatrics
Andrada Mara Ardelean, Ioana Cristina Olariu, Raluca Isac, Ruxandra Jurac, Cristiana Stolojanu, Mircea Murariu, Ana-Olivia Toma, Laurentiu Braescu, Adelina Mavrea, Gabriela Doros
Summary: This study evaluated the correlation between Speckle tracking-echocardiography (STE) and traditional biomarkers in predicting anthracycline-induced cardiotoxicity in pediatric hemato-oncology patients. The results showed that STE can be a sensitive tool for early detection and prediction of cardiotoxicity, but it should be used in conjunction with clinical findings and cardiac biomarkers.
Article
Cardiac & Cardiovascular Systems
Egle Ciburiene, Sigita Aidietiene, Greta Scerbickaite, Birute Brasiuniene, Monika Drobniene, Edita Baltruskeviciene, Tadas Zvirblis, Jelena Celutkiene
Summary: Cardio-oncology (CO) is a rapidly growing subspecialty of cardiology that aims to prevent and reverse cardiac damage caused by cancer therapies to improve the survival of cancer patients. The study findings indicate that age, previous cancer, tumor progression, kidney dysfunction, left ventricular diastolic dysfunction, and NYHA stages are associated with increased mortality.
JOURNAL OF CARDIOVASCULAR DEVELOPMENT AND DISEASE
(2022)
Article
Oncology
Zhiyue Liu, Mei Liu, Xiaorong Zhong, Yupei Qin, Ting Liang, Ting Luo, Xi Yan, Zhuoqin Tang, Xi Wang, Shichu Liang, Qian Li, Xiaomiao Ruan, Wenfeng He, He Huang
Summary: This study provides a guide for the prediction of late-onset CTR-CVT in breast cancer patients using strain and contrast-enhanced echocardiography. The results show that LV GLS decreases over time in breast cancer patients and the combination of LV GLS and c-LVEF is better in predicting CTR-CVT.
Article
Oncology
Camara L. Casson, Sofia A. John, Meghan C. Ferrall-Fairbanks
Summary: Cardiotoxicity is a common side-effect of cancer therapeutics, but the mechanisms underlying it are not well understood. Cardio-oncology focuses on understanding the effects of cancer and its treatment on the human heart. Mechanistic modeling approaches have been used to study the cardiovascular system and the effects of cancer treatments on the heart.
SEMINARS IN CANCER BIOLOGY
(2023)
Review
Oncology
Drishti Tolani, Julia Wilcox, Sharvari Shyam, Neha Bansal
Summary: As chemotherapy improves, understanding the effects on the cardiovascular system is increasingly important. Cardiotoxicity is a major determinant of morbidity and mortality in cancer survivors. New imaging modalities and biomarkers may detect subclinical cardiotoxicity earlier. Dexrazoxane remains the most effective therapy for preventing anthracycline-induced cardiomyopathy. Neurohormonal modulating drugs have not been effective in preventing cardiotoxicity. Advanced cardiac therapies, like heart transplant, should be considered for cancer survivors with end-stage HF. Research on genetic associations may produce treatments to reduce cardiovascular morbidity and mortality.
CURRENT TREATMENT OPTIONS IN ONCOLOGY
(2023)
Article
Cardiac & Cardiovascular Systems
Anthony F. Yu, I-Hsin Lin, Justine Jorgensen, Robert Copeland-Halperin, Stephanie Feldman, Ishmam Ibtida, Amare Assefa, Michelle N. Johnson, Chau T. Dang, Jennifer E. Liu, Richard M. Steingart
Summary: This study developed a nomogram consisting of 9 readily accessible clinical variables to estimate the 1-year risk of CTRCD in women with HER2-positive breast cancer receiving HER2-targeted therapy. The nomogram showed good discrimination and calibration, providing a simple-to-use tool for clinicians and patients to make decisions regarding breast cancer treatment options and cardiac surveillance frequency.
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2023)
Article
Cardiac & Cardiovascular Systems
Erin J. Howden, Steve Foulkes, Hayley T. Dillon, Ashley Bigaran, Leah Wright, Kristel Janssens, Prue Comie, Benedict Costello, Andre La Gerche
Summary: The study found that an integrative measure of cardiovascular function (VO(2)peak) may be more sensitive to cardiac damage induced by cancer treatment compared to LVEF, GLS, or cardiac biomarkers. After treatment, there was a significant reduction in VO(2)peak, while changes in LVEF and GLS were minor. This suggests that assessing VO(2)peak before and after cancer treatment may be helpful in identifying patients at increased risk of heart failure.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGING
(2021)
Article
Oncology
Lindsay L. Puckett, Shahryar G. Saba, Sonia Henry, Stacey Rosen, Elise Rooney, Samaria L. Filosa, Philip Gilbo, Karalyn Pappas, Alison Laxer, Katherine Eacobacci, Amitha N. Kapyur, Justin Robeny, Samantha Musial, Anisha Chaudhry, Rahul Chaudhry, Martin L. Lesser, Adam Riegel, Sariah Ramoutarpersaud, Navid Rahmani, Amar Shah, Vivian Papas, Toluwani Dawodu, Jessica Charlton, Jonathan P. S. Knisely, Lucille Lee
Summary: This study identified a high incidence of cardiovascular disease in heterogeneous long-term breast cancer survivors, with over half having clinical findings warranting follow-up and/or intervention. Each imaging test independently contributed to the detection rate, suggesting that long-term cardiac screening may be valuable for a wider group of breast cancer survivors than previously recognized.
Review
Pharmacology & Pharmacy
Miki Nonaka, Hiroshi Hosoda, Yasuhito Uezono
Summary: Advances in cancer treatment have improved outcomes and led to an increase in cancer survivors, but also raise concerns about cardiovascular complications. It is important to consider both the prognosis and quality of life of cancer patients, and to take measures to prevent and treat cancer treatment-related cardiovascular diseases.
BIOCHEMICAL PHARMACOLOGY
(2021)
Review
Cardiac & Cardiovascular Systems
Flavio D'Ascenzi, Francesca Anselmi, Caterina Fiorentini, Roberta Mannucci, Marco Bonifazi, Sergio Mondillo
Summary: This review focuses on investigating the origin, prevention, and reversal strategies of cardiac damage, and explores the beneficial effects of physical exercise on cancer patients. It suggests personalized exercise prescriptions and emphasizes the importance of cardiac evaluation in prescribing exercise for these patients.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY
(2021)
Article
Oncology
Julia Pohl, Raluca-Ileana Mincu, Simone M. Mrotzek, Reza Wakili, Amir A. Mahabadi, Sophia K. Potthoff, Jens T. Siveke, Ulrich Keller, Ulf Landmesser, Tienush Rassaf, Markus S. Anker, Matthias Totzeck
Summary: This study evaluated a new electrocardiographic (ECG) score in therapy-naive cancer patients to predict cardiotoxicity, showing that an ECG score of >= 2 points was associated with a higher risk of developing cardiotoxicity. High-risk patients did not differ in age, LV ejection fraction, cardiovascular risk factors, or cardiac biomarkers compared to those with a low-risk ECG score.
Review
Cardiac & Cardiovascular Systems
Yinghui Wang, Yonggang Wang, Xiaorong Han, Jian Sun, Cheng Li, Binay Kumar Adhikari, Jin Zhang, Xiao Miao, Zhaoyang Chen
Summary: Cardiovascular disease (CVD) and cancer are leading causes of death worldwide. The adverse effects of anti-tumor therapy, particularly on the cardiovascular system, have gained significant attention. Incidence of cardiovascular events is higher than tumor recurrence rate, and CVD and malignant tumors share common risk factors. Clinicians should understand this relationship, provide primary and secondary prevention strategies, and follow proper treatment methods.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2022)